Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam-Reference-Cited by-同舟云学术

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam

Published:2023-04-13 Issue:2 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Koumaki Vasiliki¹²,Dokoumetzidis Aristides³,Angelerou Maria Galini Faidra³,Baka Stavroula²,Balakrishnan Indran⁴,Tsakris Athanasios¹^ORCID

Affiliation:

1. Department of Microbiology, Medical School, University of Athens, Athens, Greece

2. Department of Microbiology, Aretaieion Hospital, University of Athens, Athens, Greece

3. Department of Pharmacy, University of Athens, Athens, Greece

4. Department of Medical Microbiology, Royal Free London NHS Foundation Trust, London, United Kingdom

Abstract

Previous studies have shown that intravenous mecillinam might be suitable for treatment of urosepsis. Since multidrug-resistant Enterobacterales are common pathogens in such infections, an effort was made to delineate intermittent, extended, and continuous infusion regimens that could cover pathogens exhibiting relatively higher mecillinam MICs than the wild-type strains.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.03441-22

Reference18 articles.

1. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria

2. Pivmecillinam?therapy of choice for lower urinary tract infection

3. Intravenous mecillinam compared with other β-lactams as targeted treatment for Escherichia coli or Klebsiella spp. bacteraemia with urinary tract focus

4. Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review

5. In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase